This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,703.22 Firm Fixed Price contract is for the delivery of Quillivant XR 25 mg/5 ml suspension, a specialty medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). The contract does not have a set-aside designation, indicating open competition.
The award is associated with AmerisourceBergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The contract delivery will take place in Conshohocken, Pennsylvania by the ultimate completion date of December 17, 2024.
Generated 3/17/25, 9:57 AM